Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GD-11 for injection in acute ischemic stroke (phase II, China)
CTR20222803Phase 2Completed
- Sponsor
- Jiangsu Wengao Pharmaceutical
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of GD-11 in ischemic stroke, sponsored by Jiangsu Wengao Pharmaceutical. Started Nov 2022; status: completed.
02
Drugs
GD-11
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on CTR20222803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222803.